Novartis v. Teva: Six Nilotinib Patents, Voluntary Dismissal in 62 Days
Novartis AG sued Teva Pharmaceutical Industries over six patents covering nilotinib hydrochloride capsules — the active ingredient in Tasigna — in the District of Delaware. Novartis voluntarily dismissed all claims without prejudice just 62 days after filing, leaving its enforcement options intact.
Novartis drops Teva nilotinib suit before substantive litigation begins
On April 4, 2024, Novartis AG and Novartis Pharmaceuticals Corporation filed a patent infringement action against Teva Pharmaceutical Industries, Ltd. and Teva Pharmaceuticals USA, Inc. in the District of Delaware before Judge Gregory B. Williams. The complaint asserted six U.S. patents — US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2 — against Teva’s proposed nilotinib hydrochloride capsules at the 50 mg, 150 mg, and 200 mg dosage strengths, which correspond to the formulations marketed by Novartis as Tasigna.
On June 5, 2024, Novartis filed a voluntary notice of dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), terminating all claims without prejudice. Because this rule permits unilateral dismissal before a defendant has served an answer or a motion for summary judgment, no court order was required and no merits ruling was issued. A dismissal without prejudice means Novartis retains the right to re-file claims on the same patents against Teva’s nilotinib product at a later date.
The 62-day duration is notably short even for an early voluntary dismissal, suggesting the parties may have reached a preliminary commercial or licensing arrangement — or that Novartis elected to reassess its litigation strategy before incurring substantial costs. The public record is silent on whether any agreement accompanied the dismissal, and no defendant law firm entered an appearance. The lack of any substantive docket activity between filing and dismissal is consistent with a pre-litigation resolution or a strategic pause.
Filing to Dismissed without Prejudice in 62 days
62 days — resolved before any substantive court rulings
Voluntarily dismissed: what the Rule 41 notice means for both parties
Rule 41(a)(1)(A)(i) allows plaintiff to dismiss unilaterally
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order at any time before the opposing party serves an answer or a motion for summary judgment. Because no defendant counsel entered an appearance and no responsive pleading was filed, Novartis could — and did — terminate the case by filing a single notice. No judicial approval was needed and no merits were examined.
No court order requiredWithout prejudice vs. with prejudice: the public record is silent
A dismissal without prejudice preserves the plaintiff’s right to re-file the same claims; a dismissal with prejudice extinguishes them permanently. The Novartis notice explicitly states ‘without prejudice,’ meaning Novartis retains full enforcement rights against Teva’s nilotinib product on all six asserted patents. Whether any private agreement accompanied this filing — such as a consent judgment, licensing term, or covenant not to sue — is not disclosed in the public record.
Re-filing rights preservedNovartis retains all enforcement options on nilotinib patents
By dismissing without prejudice, Novartis avoids any adverse ruling on the merits of its six nilotinib patents while keeping the option to re-assert them against Teva — or any other generic entrant — in future proceedings. This approach is commonly used when parties reach a licensing or settlement-in-principle that has not yet been fully documented, or when a plaintiff elects to recalibrate before committing to full litigation costs.
Patents remain enforceableTeva faces continued patent uncertainty on its nilotinib ANDA
Teva secured no invalidity ruling, no non-infringement determination, and no covenant not to sue on the six Novartis patents — at least none visible in the public record. The dismissal without prejudice means the litigation risk attached to Teva’s nilotinib ANDA has not been formally resolved. Generic launch decisions would typically require careful monitoring of whether Novartis re-files or the patents expire before any commercial entry.
No clearance on validity or infringementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator — holder of six nilotinib hydrochloride formulation patentsSearch in Eureka ↗ |
| Co-Plaintiff | Novartis, AG | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Generic pharmaceutical manufacturer seeking to market nilotinib hydrochloride capsulesSearch in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) explicitly, confirming this was a unilateral plaintiff action requiring no judicial involvement. The phrase ‘without prejudice’ is legally operative: it leaves all six patent infringement claims alive for potential re-assertion. Notably, no defendant appeared of record, which is consistent with either a pre-filing negotiation or a strategic decision by Novartis to pause before Teva engaged counsel — leaving the substantive merits of the nilotinib infringement allegations entirely unexamined by the court.
US8389537B2 and five further patents — nilotinib hydrochloride formulations
The six asserted patents — US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2 — cover various aspects of nilotinib hydrochloride, the active ingredient in Novartis’s Tasigna, a BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. The patents span formulation chemistry, crystalline salt forms, dosage form technology, and methods of use, with application dates ranging across the 2007–2012 period, creating a layered exclusivity structure typical of innovator oncology portfolios.
Tasigna is a significant Novartis oncology franchise, and the six-patent cluster reflects a strategy of protecting the compound, its formulations, and its clinical applications through multiple independent patent families. For generic manufacturers, this layered approach means that clearing one patent is insufficient — each of the six must be independently challenged or designed around. The patents’ staggered expiry timelines, combined with potential pediatric exclusivity and patent term extensions, are likely to be the focal point of any future FTO analysis by competing ANDA filers.
Should you run an FTO against the Novartis nilotinib patent cluster?
Any pharmaceutical manufacturer, formulation scientist, or generic drug developer working on nilotinib hydrochloride capsules — at any dosage strength — should treat all six Novartis patents as active blocking risk. The absence of a court-issued invalidity or non-infringement ruling means none of these patents has been judicially cleared. Product teams planning ANDA submissions or 505(b)(2) filings should assess each patent’s claim scope, expiry, and extension status before committing to regulatory timelines.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape across all six asserted patents simultaneously, flag continuation applications and related families that may not be listed in the Orange Book, and identify prior art that could support IPR petitions. For nilotinib specifically, Eureka can cross-reference prosecution history estoppel and claim differentiation arguments that may define the boundaries of Novartis’s enforceable scope — giving your team a structured, auditable FTO output in hours rather than weeks.
Run a freedom-to-operate analysis on US8389537B2 to assess your product’s exposure
Run FTO in Eureka →Similar nilotinib and Hatch-Waxman ANDA cases in Delaware District Court
Explore related Hatch-Waxman ANDA infringement cases involving nilotinib formulation patents and oncology small-molecule generics litigated in Delaware District Court.
What this case signals for the generic pharmaceutical IP landscape
A 62-day lifecycle and silent docket suggest this ANDA dispute resolved — or paused — well before judicial scrutiny.
Early voluntary dismissals in ANDA cases often signal a licensing arrangement
When an innovator dismisses an ANDA infringement suit before the defendant even enters an appearance, it typically suggests a commercial resolution is in progress or completed. IP teams monitoring Novartis’s nilotinib portfolio should track whether any exclusivity periods or launch dates shift for Teva’s generic, as these are proxy indicators of a consent judgment or license.
Six-patent assertion strategies increase settlement leverage in Hatch-Waxman cases
Novartis filed with a six-patent cluster rather than a single lead patent, a tactic that increases the cost and complexity of a generic challenger’s invalidity analysis. Even a dismissal without prejudice preserves this leverage: each patent remains a potential basis for a new action, extending the shadow of litigation over Teva’s commercial planning for nilotinib capsules.
Novartis v Teva — key questions answered
The public record does not disclose the reason. Novartis filed a unilateral Rule 41(a)(1)(A)(i) notice — requiring no court order — just 62 days after filing. No defendant counsel appeared and no responsive pleading was filed. The dismissal without prejudice preserves Novartis’s right to re-file, which is consistent with a preliminary commercial arrangement, a licensing negotiation in progress, or a strategic decision to pause litigation.
Dismissed without prejudice means Novartis can re-file the same infringement claims on any of the six asserted patents at a future date. Teva received no non-infringement ruling and no invalidity determination. From a freedom-to-operate perspective, the dismissal provides Teva with no judicial clearance, meaning the patent risk attached to its nilotinib ANDA remains legally unresolved in the public record.
Novartis asserted six U.S. patents: US8389537B2, US9061029B2, US8163904B2, US8293756B2, US8415363B2, and US8501760B2. The patents cover nilotinib formulations, crystalline salt forms, dosage form technology, and methods of use. The product accused was Teva’s proposed nilotinib hydrochloride capsules at 50 mg, 150 mg, and 200 mg — corresponding to Novartis’s branded Tasigna dosage strengths.
Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure allows a plaintiff to dismiss an action without a court order by filing a notice before the opposing party serves an answer or a motion for summary judgment. In this case, Teva did not file any responsive pleading, so Novartis was entitled to dismiss unilaterally. The dismissal was expressly without prejudice, meaning no res judicata bar attaches to the claims.
The case lasted 62 days from April 4, 2024 to June 5, 2024. This is a notably short lifecycle for a six-patent ANDA infringement action, suggesting the parties may have reached a preliminary arrangement before substantive litigation commenced. No defendant law firm entered an appearance, which further suggests either pre-litigation negotiation or a Novartis decision to withdraw and reassess strategy before incurring significant costs.
PatSnap Eureka searches patents and litigation data to answer instantly.